These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22812555)

  • 21. [Cost-benefit analysis of [224Ra] radium chloride therapy for ankylosing spondylitis (Bekhterev's disease)].
    Zhang Z; Siegert J; Maywald U; Kirch W
    Med Klin (Munich); 2007 Jul; 102(7):540-9. PubMed ID: 17634872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?
    Merkesdal S; Zeidler H
    Curr Rheumatol Rep; 2005 Aug; 7(4):254-8. PubMed ID: 16045826
    [No Abstract]   [Full Text] [Related]  

  • 23. Indirect and direct costs of treating patients with ankylosing spondylitis in the Brazilian public health system.
    Azevedo VF; Rossetto CN; Lorencetti PG; Tramontin MY; Fornazari B; Araújo DV
    Rev Bras Reumatol Engl Ed; 2016; 56(2):131-7. PubMed ID: 27267526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
    Kobelt G
    Rheumatology (Oxford); 2008 Oct; 47(10):1589-90; author reply 1590; discussion 1590-1. PubMed ID: 18710898
    [No Abstract]   [Full Text] [Related]  

  • 25. A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.
    Temel M; Atagündüz P; Direskeneli H
    Ann Rheum Dis; 2005 Sep; 64(9):1383-4. PubMed ID: 16100352
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
    Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The role of biologic agents in the therapy of ankylosing spondylitis].
    Géher P; Nagy MB; Péntek M; Tóth E; Brodszky V; Gulácsi L
    Orv Hetil; 2006 Jul; 147(26):1203-13. PubMed ID: 16898082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
    Brandt J; Sieper J; Braun J
    Z Rheumatol; 2003 Jun; 62(3):218-27. PubMed ID: 12827397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists.
    Landewé R; Rump B; van der Heijde D; van der Linden S
    Ann Rheum Dis; 2004 May; 63(5):530-4. PubMed ID: 15082483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues.
    Jois RN; Gaffney K; Keat A
    Rheumatology (Oxford); 2007 Jun; 46(6):899-901. PubMed ID: 17308313
    [No Abstract]   [Full Text] [Related]  

  • 32. The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.
    Smith N; Gadsby K; Butt S; Deighton C
    Rheumatology (Oxford); 2007 Jun; 46(6):1044-5. PubMed ID: 17401132
    [No Abstract]   [Full Text] [Related]  

  • 33. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
    Baraliakos X; Listing J; Brandt J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Rudwaleit M; Sieper J; Braun J
    Arthritis Res Ther; 2005; 7(3):R439-44. PubMed ID: 15899030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
    Berg PA
    Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
    [No Abstract]   [Full Text] [Related]  

  • 37. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour necrosis factor inhibitors in ankylosing spondylitis.
    Reed MR; Taylor AL
    Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring patients with ankylosing spondylitis on anti-TNF monotherapy: too much too often?
    Gunasekera W; Creamer P; Creamer K; Sengupta R
    Scand J Rheumatol; 2017 Jul; 46(4):330-331. PubMed ID: 27733090
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis.
    Ma Z; Liu X; Xu X; Jiang J; Zhou J; Wang J; Chen D; Luo S
    Medicine (Baltimore); 2017 Jun; 96(25):e7145. PubMed ID: 28640088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.